You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Advanced BRCA-mutated breast cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial in Los Angeles (Pembrolizumab, Olaparib)

Active, not recruiting
  • Breast Cancer
  • Los Angeles, California
    Cedars-Sinai Medical Center
Feb 1, 2023

Breast Cancer, Ovarian Cancer, Pancreas Cancer Trial (TNG348, Olaparib)

Not yet recruiting
  • Breast Cancer
  • +7 more
  • (no location specified)
Sep 26, 2023

Advanced Breast Cancer Trial in Spain (Olaparib [Lynparza®] plus Trastuzumab [Herceptin®])

Terminated
  • Advanced Breast Cancer
  • Olaparib [Lynparza®] plus Trastuzumab [Herceptin®]
  • Barcelona, Spain
  • +16 more
Jan 18, 2023

Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 Trial in Houston

Recruiting
  • Advanced Breast Carcinoma
  • +14 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 31, 2022

Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer Trial in United States (Niraparib, Dostarlimab)

Recruiting
  • Stage I Breast Cancer
  • +7 more
  • Baltimore, Maryland
  • +6 more
Nov 11, 2022

Germline BRCA-mutated HER2-negative Breast Cancer Trial in Beijing (Camrelizumab+Fluzoparib)

Enrolling by invitation
  • Germline BRCA-mutated HER2-negative Breast Cancer
  • Beijing, Beijing, China
    Breast Cancer, Peking University People's Hospital
Nov 14, 2022

TNBC - Triple-Negative Breast Cancer Trial in Nanjing (Fluzoparib+Paclitaxel, Epirubicin+Cyclophosphamide)

Recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Nanjing, Jiangsu, China
    JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Apr 27, 2023

LYNPARZA Breast Cancer in Adjuvant Setting Japan Post-Marketing

Not yet recruiting
  • Breast Cancer
    • (no location specified)
    Jan 9, 2023

    Triple Negative Breast Tumors, Triple Negative Breast Cancer, Breast Tumors Trial (Pembrolizumab, Paclitaxel, Carboplatin)

    Not yet recruiting
    • Triple Negative Breast Neoplasms
    • +7 more
    • (no location specified)
    Aug 1, 2022

    Breast Cancer, Breast Cancer Metastatic Trial in Spain (Niraparib 100 MG, Aromatase Inhibitors)

    Terminated
    • Breast Cancer
    • Breast Cancer Metastatic
    • Niraparib 100 MG
    • Aromatase Inhibitors
    • A Coruña, Spain
    • +9 more
    Jan 17, 2023

    Ovarian Cancer, Breast Cancer Trial in Vijayawada (Olaparib tablets, 150 mg, Lynparza® (olaparib) tablets 150 mg)

    Recruiting
    • Ovarian Cancer
    • Breast Cancer
    • Olaparib tablets, 150 mg
    • Lynparza® (olaparib) tablets 150 mg
    • Vijayawada, Andhra Pradesh, India
      Sandoz Investigative Site
    Apr 12, 2022

    Breast Cancer, Genetic Disease, BRCA2 Mutation Trial (blood sample for BRCA2 mutation detection)

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • blood sample for BRCA2 mutation detection
    • (no location specified)
    Jun 1, 2023

    Breast Cancer Trial (Inavolisib, Fulvestrant, Alpelisib)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Jan 30, 2023

    Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)

    Active, not recruiting
    • Advanced Breast Cancer
    • +2 more
    • Talazoparib Tosylate
    • Stanford, California
      Stanford University Hospitals and Clinics
    Nov 16, 2022

    BRCA and NACT in TNBC Patients

    Completed
    • Triple-Negative Breast Cancer
    • BRCA1/2 genetic testing
    • Rome, RM, Italy
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Feb 20, 2023

    Advanced Solid Tumor, NSCLCs Trial in Houston (Adagrasib, Olaparib)

    Not yet recruiting
    • Advanced Solid Tumor
    • Non-small Cell Lung Cancers
    • Houston, Texas
      M D Anderson Cancer Center
    Nov 15, 2023

    Metastatic Breast Cancer Trial (Inavolisib, Phesgo, Placebo)

    Not yet recruiting
    • Metastatic Breast Cancer
    • (no location specified)
    Jun 7, 2023

    Advanced Colorectal Cancer Trial in Hangzhou (Cetuximab Dabrafenib Tislelizumab)

    Not yet recruiting
    • Advanced Colorectal Cancer
    • Cetuximab Dabrafenib Tislelizumab
    • Hangzhou, Zhejing, China
      Zhejiang Cancer Institute & Hospital
    Jul 19, 2023

    HER2-negative Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer Trial in Spain (Olaparib)

    Recruiting
    • HER2-negative Breast Cancer
    • +2 more
    • Barcelona, Spain
    • +4 more
    Apr 14, 2022

    Breast Cancer Metastatic Trial in Beijing (TSL-1502 capsules(low dose), TSL-1502 capsules(high dose), Investigator's choice of

    Not yet recruiting
    • Breast Cancer Metastatic
    • TSL-1502 capsules(low dose)
    • +2 more
    • Beijing, China
      Cancer Hospital, Chinese Academy of Medical Sciences
    Jun 13, 2022

    ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a

    Recruiting
    • ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
    • a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
    • Montpellier, France
    • +1 more
    Nov 16, 2022

    Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation Trial in Boston (ABT-888, temozolomide)

    Active, not recruiting
    • Breast Cancer
    • +3 more
    • Boston, Massachusetts
    • +2 more
    Dec 21, 2022

    Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8

    Recruiting
    • Anatomic Stage III Breast Cancer AJCC v8
    • +51 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Mar 15, 2022

    Breast Cancer After Ovarian Cancer During and/or After Therapy:

    Recruiting
    • BRCA-Associated Breast Carcinoma
    • Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).
    • Rome, RM, Italy
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Mar 9, 2023

    HR+, HER2-, Advanced Breast Cancer Trial (alpelisib)

    Available
    • HR+, HER2-, Advanced Breast Cancer
    • (no location specified)
    Jul 5, 2022